NCT07414719 Impact of an HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in the AuRA Region.
| NCT ID | NCT07414719 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Leon Berard |
| Condition | Middle School and High School Students |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,422 participants |
| Start Date | 2025-12-16 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,422 participants in total. It began in 2025-12-16 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Human papillomaviruses (HPV) are very common contagious viruses: approximately 70% of men and women will be infected during their lifetime. Vaccination, recommended since 2007 for girls and since 2021 for all young people aged 11 to 14 (with catch-up vaccination possible up to age 26), remains insufficiently followed. Today, only 40.7% of adolescents are vaccinated in France, and the Auvergne Rhône Alpes region remains below the targets (47.5% for girls and 12.3% for boys). This is still far from the national target of 80% vaccination coverage by 2030, while 6,400 new cases of HPV-related cancers are reported each year. The PIMCOP regional study aims to assess the impact of a primary prevention intervention, co-developed with stakeholders and implemented in middle and high schools, on the HPV vaccination rate at 6 months among 11-17 year olds.
Eligibility Criteria
Inclusion Criteria for children : * Girl or boy, student at a public school participating in the study * Aged 11 to 17 * Having received an information sheet about the study and having signed a declaration of non-objection * Whose parents have also received an information sheet and have not expressed their non-objection * Able to read, write, and understand French * Affiliated with the SS or equivalent Exclusion Criteria for children: * children protected by the law Inclusion Criteria for teachers : * Male or female, teacher at a public school participating in the study and supervising a participating class * Aged 18 or over * Having received an information sheet about the study and not having expressed their opposition * Able to read, write, and understand French * Affiliated with the SS or equivalent Exclusion Criteria for teachers : \- Person specially protected by law
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07414719 clinical trial?
This trial is open to participants of all sexes, aged 11 Years or older, up to 17 Years, studying Middle School and High School Students. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07414719 currently recruiting?
Yes, NCT07414719 is actively recruiting participants. Contact the research team at carmen.dupuis@lyon.unicancer.fr for enrollment information.
Where is the NCT07414719 trial being conducted?
This trial is being conducted at Saint-Priest, France.
Who is sponsoring the NCT07414719 clinical trial?
NCT07414719 is sponsored by Centre Leon Berard. The trial plans to enroll 1,422 participants.